Literature DB >> 1324648

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.

J J Eron1, V A Johnson, D P Merrill, T C Chou, M S Hirsch.   

Abstract

The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by the median-effect principle and isobologram techniques. Cytotoxicity of the agents was not observed. Clinical trials are ongoing to define the combination's role in HIV-1 therapy.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1324648      PMCID： PMC191620          DOI： 10.1128/AAC.36.7.1559

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.

Authors:  D D Richman; J M Grimes; S W Lagakos
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

Review 3.  Molecular targets for AIDS therapy.

Authors:  H Mitsuya; R Yarchoan; S Broder
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

4.  Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

Authors:  V A Johnson; D P Merrill; J A Videler; T C Chou; R E Byington; J J Eron; R T D'Aquila; M S Hirsch
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

5.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

6.  Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.

Authors:  T P Cooley; L M Kunches; C A Saunders; J K Ritter; C J Perkins; C McLaren; R P McCaffrey; H A Liebman
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

7.  Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.

Authors:  T C Meng; M A Fischl; A M Boota; S A Spector; D Bennett; Y Bassiakos; S H Lai; B Wright; D D Richman
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

8.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

9.  Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

Authors:  H Mitsuya; R F Jarrett; M Matsukura; F Di Marzo Veronese; A L DeVico; M G Sarngadharan; D G Johns; M S Reitz; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728
View more
  21 in total

1.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

2.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 3.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.

Authors:  C A Deminie; C M Bechtold; D Stock; M Alam; F Djang; A H Balch; T C Chou; M Prichard; R J Colonno; P F Lin
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 5.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 6.  Combinatorial approaches to the prevention and treatment of HIV-1 infection.

Authors:  Vanessa Pirrone; Nina Thakkar; Jeffrey M Jacobson; Brian Wigdahl; Fred C Krebs
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

7.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

Review 8.  Zalcitabine. Clinical pharmacokinetics and efficacy.

Authors:  D Devineni; J M Gallo
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Authors:  Rima Kulkarni; Rebecca Hluhanich; Damian M McColl; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

10.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.